Aricept Odt is a drug owned by Eisai Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 23, 2022. Details of Aricept Odt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7727548 | Rapidly disintegrable tablet containing polyvinyl alcohol |
Jun, 2022
(2 years ago) |
Expired
|
| US7727552 | Oral pharmaceutical preparations decreased in bitterness by masking |
Mar, 2018
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aricept Odt's patents.
Latest Legal Activities on Aricept Odt's Patents
Given below is the list of recent legal activities going on the following patents of Aricept Odt.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 02 Jul, 2018 | US7727548 |
| Maintenance Fee Reminder Mailed Critical | 15 Jan, 2018 | US7727548 |
| Email Notification Critical | 03 Mar, 2016 | US7727548 |
| Change in Power of Attorney (May Include Associate POA) Critical | 03 Mar, 2016 | US7727548 |
| Correspondence Address Change Critical | 02 Mar, 2016 | US7727548 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Jun, 2010 | US7727548 |
| Recordation of Patent Grant Mailed Critical | 01 Jun, 2010 | US7727548 |
| Email Notification Critical | 13 May, 2010 | US7727548 |
| Issue Notification Mailed Critical | 12 May, 2010 | US7727548 |
| Dispatch to FDC | 13 Apr, 2010 | US7727548 |
US patents provide insights into the exclusivity only within the United States, but Aricept Odt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Aricept Odt's family patents as well as insights into ongoing legal events on those patents.
Aricept Odt's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Aricept Odt's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 23, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Aricept Odt Generic API suppliers:
Donepezil Hydrochloride is the generic name for the brand Aricept Odt. 39 different companies have already filed for the generic of Aricept Odt, with Chartwell Rx having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Aricept Odt's generic
How can I launch a generic of Aricept Odt before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Aricept Odt's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Aricept Odt's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Aricept Odt -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 5 mg and 10 mg | 30 Jun, 2010 | 1 | 26 Nov, 2010 | 23 Jun, 2022 | Extinguished |
Alternative Brands for Aricept Odt
Aricept Odt which is used for treating Alzheimer's disease., has several other brand drugs using the same active ingredient (Donepezil Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Donepezil Hydrochloride, Aricept Odt's active ingredient. Check the complete list of approved generic manufacturers for Aricept Odt
About Aricept Odt
Aricept Odt is a drug owned by Eisai Inc. It is used for treating Alzheimer's disease. Aricept Odt uses Donepezil Hydrochloride as an active ingredient. Aricept Odt was launched by Eisai Inc in 2004.
Approval Date:
Aricept Odt was approved by FDA for market use on 18 October, 2004.
Active Ingredient:
Aricept Odt uses Donepezil Hydrochloride as the active ingredient. Check out other Drugs and Companies using Donepezil Hydrochloride ingredient
Treatment:
Aricept Odt is used for treating Alzheimer's disease.
Dosage:
Aricept Odt is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 10MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |